Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Innate grosses €20.3mm through private placement to US investors

Executive Summary

Innate Pharma SA (immunotherapies for cancer and inflammatory diseases) grossed €20.3mm ($27.3mm) through the sale of 7.6mm ordinary shares at €2.67 apiece (a 6% premium). The financing was subscribed entirely by US investors, including OrbiMed (which took a stake in Innate of over 5%), and funds managed by QVT Financial and Redmile Group.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies